article thumbnail

Acute lymphocytic leukaemia leads in cell therapy clinical development

Pharmaceutical Technology

Despite the market size for B-cell non-Hodgkin’s lymphoma (NHL) being at least five times that of ALL, NHL has a smaller pipeline of cell therapies. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

article thumbnail

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. There are currently over 700 immuno-oncology products in Phase I-III of development in the eight major markets, said Chalk.

Marketing 264
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Diversity, Equity, and Inclusion Data Service for clinical development 

Drug Discovery World

Dr Pooja Phogat, co-founder and co-CEO of Krystelis, said: “The new service will make the development process easier for sponsors and help them to ensure they are meeting new, more stringent, regulatory requirements.

article thumbnail

Entrance of novel therapies will drive Niemann-Pick type C disease market growth

Pharmaceutical Technology

According to GlobalData’s recent Niemann-Pick Type C (NPC): Opportunity Analysis and Forecast to 2031 report, the NPC market is expected to see significant growth during 2021–31. This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market.

Marketing 306
article thumbnail

Bristol Myers Squibb secures EC marketing approval for anemia therapy

Pharmaceutical Technology

Bristol Myers Squibb has secured complete marketing authorisation from the European Commission (EC) for Reblozyl (luspatercept) to treat anaemia in adult patients with non-transfusion dependent (NTD) beta-thalassemia. The post Bristol Myers Squibb secures EC marketing approval for anemia therapy appeared first on Pharmaceutical Technology.

Marketing 147
article thumbnail

HEOR and Market Access Strategies in Today’s Drug Development Landscape – Insights from AstraZeneca’s Dr. Heather McDonald

XTalks

Health economics and outcomes research (HEOR) and market access strategies play a critical role in ensuring that newly approved therapies are made available to patients. Professionals in these roles are facing new challenges when it comes to negotiating coverage for many of the new, innovative treatments that are coming to market.

Marketing 105
article thumbnail

Webinar: Avoid unnecessary delays getting cell therapies to market

Drug Discovery World

Both GTPs and GMPs must be followed to get cell-based advanced therapies or tissue-based therapy products to market. Can a manufacturer of a cell or gene therapy switch suppliers midstream in clinical development? What are the costs and time delays of switching suppliers later in clinical development?